(A) Agilent Technologies - Overview
Sector: HealthcareIndustry: Diagnostics & Research | Exchange NYSE (USA) | Currency USD | Market Cap: 31.480m | Total Return -6.6% in 12m
Stock: Instruments, Software, Services, Consumables, Genomics
Total Rating 49
Risk 87
Buy Signal -1.12
| Risk 5d forecast | |
|---|---|
| Volatility | 30.0% |
| Relative Tail Risk | -6.56% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.19 |
| Alpha | -21.02 |
| Character TTM | |
|---|---|
| Beta | 1.106 |
| Beta Downside | 1.008 |
| Drawdowns 3y | |
|---|---|
| Max DD | 35.31% |
| CAGR/Max DD | -0.19 |
EPS (Earnings per Share)
Revenue
Description: A Agilent Technologies March 04, 2026
Agilent Technologies Inc. (A) provides analytical instrumentation and solutions across the life sciences, diagnostics, and applied chemical markets. The company operates in three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The Life Sciences segment offers chromatography and mass spectrometry systems, catering to genomics and biomolecular analysis, a growing area within healthcare research.
The Agilent CrossLab segment focuses on services and consumables, including repairs, maintenance, and software-as-a-service (SaaS) offerings. This recurring revenue model is common in the scientific instrumentation sector, providing stable income streams. The Applied Markets segment supplies gas chromatography, mass spectrometry, and spectroscopy products.
Agilent distributes its products through direct sales, distributors, and e-commerce. Further investigation into financial metrics can be found on ValueRay.
Headlines to watch out for
- Life sciences research spending drives instrument demand
- Diagnostics market expansion boosts revenue growth
- Lab services and consumables provide recurring income
- Global economic conditions impact capital equipment sales
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 1.29b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA -3.26 > 1.0 |
| NWC/Revenue: 33.70% < 20% (prev 34.26%; Δ -0.56% < -1%) |
| CFO/TA 0.11 > 3% & CFO 1.40b > Net Income 1.29b |
| Net Debt (1.60b) to EBITDA (1.82b): 0.88 < 3 |
| Current Ratio: 2.07 > 1.5 & < 3 |
| Outstanding Shares: last quarter (284.0m) vs 12m ago -1.05% < -2% |
| Gross Margin: 52.23% > 18% (prev 0.54%; Δ 5.17k% > 0.5%) |
| Asset Turnover: 57.14% > 50% (prev 54.83%; Δ 2.31% > 0%) |
| Interest Coverage Ratio: 14.14 > 6 (EBITDA TTM 1.82b / Interest Expense TTM 109.0m) |
Altman Z'' 2.67
| A: 0.19 (Total Current Assets 4.62b - Total Current Liabilities 2.23b) / Total Assets 12.81b |
| B: 0.12 (Retained Earnings 1.48b / Total Assets 12.81b) |
| C: 0.12 (EBIT TTM 1.54b / Avg Total Assets 12.36b) |
| D: 0.22 (Book Value of Equity 1.30b / Total Liabilities 5.91b) |
| Altman-Z'' Score: 2.67 = A |
Beneish M -2.93
| DSRI: 1.06 (Receivables 1.52b/1.33b, Revenue 7.07b/6.53b) |
| GMI: 1.03 (GM 52.23% / 53.97%) |
| AQI: 0.95 (AQ_t 0.48 / AQ_t-1 0.50) |
| SGI: 1.08 (Revenue 7.07b / 6.53b) |
| TATA: -0.01 (NI 1.29b - CFO 1.40b) / TA 12.81b) |
| Beneish M-Score: -2.93 (Cap -4..+1) = A |
What is the price of A shares?
As of March 29, 2026, the stock is trading at USD 110.24 with a total of 1,264,563 shares traded.
Over the past week, the price has changed by -0.95%, over one month by -9.18%, over three months by -19.93% and over the past year by -6.59%.
Over the past week, the price has changed by -0.95%, over one month by -9.18%, over three months by -19.93% and over the past year by -6.59%.
Is A a buy, sell or hold?
Agilent Technologies has received a consensus analysts rating of 4.00.
Therefore, it is recommended to buy A.
- StrongBuy: 9
- Buy: 2
- Hold: 9
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the A price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 163.3 | 48.1% |
| Analysts Target Price | 163.3 | 48.1% |
A Fundamental Data Overview March 29, 2026
P/E Trailing = 24.5695
P/E Forward = 18.7266
P/S = 4.4558
P/B = 4.5532
P/EG = 1.1638
Revenue TTM = 7.07b USD
EBIT TTM = 1.54b USD
EBITDA TTM = 1.82b USD
Long Term Debt = 3.05b USD (from longTermDebt, last quarter)
Short Term Debt = 304.0m USD (from shortTermDebt, last quarter)
Debt = 3.35b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.60b USD (from netDebt column, last quarter)
Enterprise Value = 33.08b USD (31.48b + Debt 3.35b - CCE 1.76b)
Interest Coverage Ratio = 14.14 (Ebit TTM 1.54b / Interest Expense TTM 109.0m)
EV/FCF = 33.31x (Enterprise Value 33.08b / FCF TTM 993.0m)
FCF Yield = 3.00% (FCF TTM 993.0m / Enterprise Value 33.08b)
FCF Margin = 14.06% (FCF TTM 993.0m / Revenue TTM 7.07b)
Net Margin = 18.26% (Net Income TTM 1.29b / Revenue TTM 7.07b)
Gross Margin = 52.23% ((Revenue TTM 7.07b - Cost of Revenue TTM 3.38b) / Revenue TTM)
Gross Margin QoQ = 52.61% (prev 51.80%)
Tobins Q-Ratio = 2.58 (Enterprise Value 33.08b / Total Assets 12.81b)
Interest Expense / Debt = 0.75% (Interest Expense 25.0m / Debt 3.35b)
Taxrate = 16.21% (59.0m / 364.0m)
NOPAT = 1.29b (EBIT 1.54b * (1 - 16.21%))
Current Ratio = 2.07 (Total Current Assets 4.62b / Total Current Liabilities 2.23b)
Debt / Equity = 0.49 (Debt 3.35b / totalStockholderEquity, last quarter 6.91b)
Debt / EBITDA = 0.88 (Net Debt 1.60b / EBITDA 1.82b)
Debt / FCF = 1.61 (Net Debt 1.60b / FCF TTM 993.0m)
Total Stockholder Equity = 6.54b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.43% (Net Income 1.29b / Total Assets 12.81b)
RoE = 19.73% (Net Income TTM 1.29b / Total Stockholder Equity 6.54b)
RoCE = 16.07% (EBIT 1.54b / Capital Employed (Equity 6.54b + L.T.Debt 3.05b))
RoIC = 12.99% (NOPAT 1.29b / Invested Capital 9.94b)
WACC = 8.98% (E(31.48b)/V(34.83b) * Re(9.87%) + D(3.35b)/V(34.83b) * Rd(0.75%) * (1-Tc(0.16)))
Discount Rate = 9.87% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -81.65 | Cagr: -1.21%
[DCF] Terminal Value 74.52% ; FCFF base≈1.12b ; Y1≈1.09b ; Y5≈1.10b
[DCF] Fair Price = 53.03 (EV 16.58b - Net Debt 1.60b = Equity 14.99b / Shares 282.6m; r=8.98% [WACC]; 5y FCF grow -3.53% → 3.0% )
EPS Correlation: 27.33 | EPS CAGR: 5.06% | SUE: -0.23 | # QB: 0
Revenue Correlation: 17.95 | Revenue CAGR: 3.04% | SUE: -0.40 | # QB: 0
EPS next Quarter (2026-04-30): EPS=1.41 | Chg7d=-0.000 | Chg30d=+0.015 | Revisions Net=+5 | Analysts=15
EPS current Year (2026-10-31): EPS=5.97 | Chg7d=+0.000 | Chg30d=+0.032 | Revisions Net=+10 | Growth EPS=+6.7% | Growth Revenue=+6.3%
EPS next Year (2027-10-31): EPS=6.56 | Chg7d=+0.005 | Chg30d=+0.010 | Revisions Net=+8 | Growth EPS=+10.0% | Growth Revenue=+6.1%
[Analyst] Revisions Ratio: +0.33 (10 Up / 5 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.8% (Discount Rate 9.9% - Earnings Yield 4.1%)
[Growth] Growth Spread = +2.0% (Analyst 7.8% - Implied 5.8%)
P/E Forward = 18.7266
P/S = 4.4558
P/B = 4.5532
P/EG = 1.1638
Revenue TTM = 7.07b USD
EBIT TTM = 1.54b USD
EBITDA TTM = 1.82b USD
Long Term Debt = 3.05b USD (from longTermDebt, last quarter)
Short Term Debt = 304.0m USD (from shortTermDebt, last quarter)
Debt = 3.35b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 1.60b USD (from netDebt column, last quarter)
Enterprise Value = 33.08b USD (31.48b + Debt 3.35b - CCE 1.76b)
Interest Coverage Ratio = 14.14 (Ebit TTM 1.54b / Interest Expense TTM 109.0m)
EV/FCF = 33.31x (Enterprise Value 33.08b / FCF TTM 993.0m)
FCF Yield = 3.00% (FCF TTM 993.0m / Enterprise Value 33.08b)
FCF Margin = 14.06% (FCF TTM 993.0m / Revenue TTM 7.07b)
Net Margin = 18.26% (Net Income TTM 1.29b / Revenue TTM 7.07b)
Gross Margin = 52.23% ((Revenue TTM 7.07b - Cost of Revenue TTM 3.38b) / Revenue TTM)
Gross Margin QoQ = 52.61% (prev 51.80%)
Tobins Q-Ratio = 2.58 (Enterprise Value 33.08b / Total Assets 12.81b)
Interest Expense / Debt = 0.75% (Interest Expense 25.0m / Debt 3.35b)
Taxrate = 16.21% (59.0m / 364.0m)
NOPAT = 1.29b (EBIT 1.54b * (1 - 16.21%))
Current Ratio = 2.07 (Total Current Assets 4.62b / Total Current Liabilities 2.23b)
Debt / Equity = 0.49 (Debt 3.35b / totalStockholderEquity, last quarter 6.91b)
Debt / EBITDA = 0.88 (Net Debt 1.60b / EBITDA 1.82b)
Debt / FCF = 1.61 (Net Debt 1.60b / FCF TTM 993.0m)
Total Stockholder Equity = 6.54b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.43% (Net Income 1.29b / Total Assets 12.81b)
RoE = 19.73% (Net Income TTM 1.29b / Total Stockholder Equity 6.54b)
RoCE = 16.07% (EBIT 1.54b / Capital Employed (Equity 6.54b + L.T.Debt 3.05b))
RoIC = 12.99% (NOPAT 1.29b / Invested Capital 9.94b)
WACC = 8.98% (E(31.48b)/V(34.83b) * Re(9.87%) + D(3.35b)/V(34.83b) * Rd(0.75%) * (1-Tc(0.16)))
Discount Rate = 9.87% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -81.65 | Cagr: -1.21%
[DCF] Terminal Value 74.52% ; FCFF base≈1.12b ; Y1≈1.09b ; Y5≈1.10b
[DCF] Fair Price = 53.03 (EV 16.58b - Net Debt 1.60b = Equity 14.99b / Shares 282.6m; r=8.98% [WACC]; 5y FCF grow -3.53% → 3.0% )
EPS Correlation: 27.33 | EPS CAGR: 5.06% | SUE: -0.23 | # QB: 0
Revenue Correlation: 17.95 | Revenue CAGR: 3.04% | SUE: -0.40 | # QB: 0
EPS next Quarter (2026-04-30): EPS=1.41 | Chg7d=-0.000 | Chg30d=+0.015 | Revisions Net=+5 | Analysts=15
EPS current Year (2026-10-31): EPS=5.97 | Chg7d=+0.000 | Chg30d=+0.032 | Revisions Net=+10 | Growth EPS=+6.7% | Growth Revenue=+6.3%
EPS next Year (2027-10-31): EPS=6.56 | Chg7d=+0.005 | Chg30d=+0.010 | Revisions Net=+8 | Growth EPS=+10.0% | Growth Revenue=+6.1%
[Analyst] Revisions Ratio: +0.33 (10 Up / 5 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.8% (Discount Rate 9.9% - Earnings Yield 4.1%)
[Growth] Growth Spread = +2.0% (Analyst 7.8% - Implied 5.8%)